These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 28007776)

  • 1. Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer.
    Balli D; Rech AJ; Stanger BZ; Vonderheide RH
    Clin Cancer Res; 2017 Jun; 23(12):3129-3138. PubMed ID: 28007776
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
    Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
    Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
    Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H
    Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
    Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
    J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
    Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
    Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell programming in pancreatic adenocarcinoma: a review.
    Seo YD; Pillarisetty VG
    Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
    Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
    Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer.
    Mirlekar B; Michaud D; Searcy R; Greene K; Pylayeva-Gupta Y
    Cancer Immunol Res; 2018 Sep; 6(9):1014-1024. PubMed ID: 29980536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma.
    Schmiechen ZC; Stromnes IM
    Front Immunol; 2020; 11():613815. PubMed ID: 33584701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.
    Hutcheson J; Balaji U; Porembka MR; Wachsmann MB; McCue PA; Knudsen ES; Witkiewicz AK
    Clin Cancer Res; 2016 Jul; 22(14):3606-17. PubMed ID: 26858311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cell-Derived IL35 Drives STAT3-Dependent CD8
    Mirlekar B; Michaud D; Lee SJ; Kren NP; Harris C; Greene K; Goldman EC; Gupta GP; Fields RC; Hawkins WG; DeNardo DG; Rashid NU; Yeh JJ; McRee AJ; Vincent BG; Vignali DAA; Pylayeva-Gupta Y
    Cancer Immunol Res; 2020 Mar; 8(3):292-308. PubMed ID: 32024640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers.
    Knudsen ES; Vail P; Balaji U; Ngo H; Botros IW; Makarov V; Riaz N; Balachandran V; Leach S; Thompson DM; Chan TA; Witkiewicz AK
    Clin Cancer Res; 2017 Aug; 23(15):4429-4440. PubMed ID: 28348045
    [No Abstract]   [Full Text] [Related]  

  • 14. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance.
    Fearon DT
    Cancer Immunol Res; 2014 Mar; 2(3):187-93. PubMed ID: 24778314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
    Blair AB; Zheng L
    Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.
    Rech AJ; Dada H; Kotzin JJ; Henao-Mejia J; Minn AJ; Twyman-Saint Victor C; Vonderheide RH
    Cancer Res; 2018 Aug; 78(15):4282-4291. PubMed ID: 29844122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.
    Shibuya KC; Goel VK; Xiong W; Sham JG; Pollack SM; Leahy AM; Whiting SH; Yeh MM; Yee C; Riddell SR; Pillarisetty VG
    PLoS One; 2014; 9(5):e96565. PubMed ID: 24794217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma.
    Stromnes IM; Hulbert A; Pierce RH; Greenberg PD; Hingorani SR
    Cancer Immunol Res; 2017 Nov; 5(11):978-991. PubMed ID: 29066497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.
    Chen YP; Zhang Y; Lv JW; Li YQ; Wang YQ; He QM; Yang XJ; Sun Y; Mao YP; Yun JP; Liu N; Ma J
    Theranostics; 2017; 7(14):3585-3594. PubMed ID: 28912897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model.
    Jung JY; Ryu HJ; Lee SH; Kim DY; Kim MJ; Lee EJ; Ryu YM; Kim SY; Kim KP; Choi EY; Ahn HJ; Chang S
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.